Publications

Selected publications from ANZSA supported researchers.

2018
2017
2016
2015
2014
2013
2012
2011
  • Gelderblom H et al. Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2018;19:639-48.
  • Liu Z et al. Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood. Cancer Chemother Pharmacol. 2018. https://doi.org/10.1007/s00280-018-3683-8.
  • Mark A. Miles and Christine J. Hawkins. Mutagenic assessment of chemotherapy and Smac mimetic drugs in cells with defective DNA damage response pathways.  Scientific Reports. 8(1):14421, 2018.
  • Rasmussen V et al. A comparison of Australian and French families affected by sarcoma: perceptions of genetics and incidental findings. Per Med. 2018;15:13-24.
  • Skaczkowski G et al. Do Australian adolescents’ and young adults’ experiences of cancer care influence their quality of life? Psychooncology. 2018;27:990-7.
  • Skaczkowski G et al. Factors influencing the provision of fertility counselling and impact on quality of life in adolescents and young adults with cancer. J Psychosoc Oncol. 2018;15:1-19.
  • Tan MTL et al. Patterns of care of superficial soft tissue sarcomas: it is not always just a lump. Asia Pac J Clin Oncol. 2018.
  • White V et al. Experiences of Care of Adolescents and Young Adults with Cancer in Australia. J Adolesc Young Adult Oncol. 2018;7:315-25.
  • Willis AM et al. Development and Pilot Testing of a Decision Aid for Genomic Research Participants Notified of Clinically Actionable Research Findings for Cancer Risk. J Genet Couns. 2018.
  • Xiaochun Wang, David Goldstein, Philip Crowe and Jia-Lin Yang. Anti-tumour effects and mechanisms of action of the panHER inhibitor, dacomitinib, alone and in combination with the STAT3 inhibitor, S3I-201, in human sarcoma cell lines. International Journal.
  • Ballinger ML et al. Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis. JAMA Oncol. 2017;3:1634-9.
  • Ballinger ML, Best A, Mai PL et al, Surveillance in Li Fraumeni Syndrome using whole body magnetic resonance imaging: A Meta analysis, JAMA Oncol. 2017 Aug 3. doi: 10.1001/jamaoncol.2017.1968. [Epub ahead of print] PMID: 28772291.
  • Ballinger ML, Ferris NJ, Moodie K et al, Surveillance in germline TP53 mutation carriers utilizing whole body magnetic resonance imaging, JAMA Oncol. 2017 Aug 3. doi: 10.1001/jamaoncol.2017.1355. [Epub ahead of print] No abstract available. PMID: 28772290.
  • Leroy B et al. Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. Cancer Res. 2017;77:1250-60.
  • Lewin J et al. Variations of Surveillance Practice for Patients with Bone Sarcoma: A Survey of Australian Sarcoma Clinicians. Sarcoma. 2017;2017.
  • McBride, K. A., Ballinger, M. L., Schlub, T. E., Young, M. A., Tattersall, M. H. N., Kirk, J., . . . Mitchell, G. (2017). Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial? Fam Cancer, 16(3), 423-432. doi:10.1007.
  • Peng G et al. Estimating TP53 Mutation Carrier Probability in Families with Li-Fraumeni Syndrome Using LFSPRO. Cancer Epidemiol Biomarkers Prev. 2017;26:837-844.
  • Tap WD et al. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2017;18:1089-103.
  • Bae S et al. Patterns of care for patients with advanced soft tissue sarcoma: experience from Australian sarcoma services. Clin Sarcoma Res. 2016;6:11.
  • Ballinger ML et al. Monogenic and polygenic determinants of sarcoma risk: an international genetic study. Lancet Oncol. 2016;17:1261-71.
  • Burgess A et al. Clinical Overview of MDM2/X-Targeted Therapies. Front Oncol. 2016;6:7.
  • McBride KA, Hallowell N, Tattersall MH, Kirk J, Ballinger ML, Thomas DM, Mitchell G, Young MA. 'Timing and context: important considerations in the return of genetic results to research participants.' J Community Genet. 2016 Jan;7(1):11-20. doi: 10.1007/s.
  • McBride, K. A., Hallowell, N., Tattersall, M. H., Kirk, J., Ballinger, M. L., Thomas, D. M., . . . Young, M. A. (2016). Timing and context: important considerations in the return of genetic results to research participants. J Community Genet, 7(1), 11-20.
  • McBride, K. A., Schlub, T. E., Ballinger, M. L., Thomas, D. M., & Tattersall, M. H. (2016). International survey of awareness of genetic risk in the clinical sarcoma community. Asia Pac J Clin Oncol, 12(2), 133-142. doi:10.1111/ajco.12457.
  • McCaughan GJ et al. Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma. J Hematol Oncol. 2016;9:48.
  • Tanmay M. Shekhar, Mark A. Miles, Ankita Gupte, Scott Taylor, Brianna Tascone, Carl R. Walkley and Christine J. Hawkins, IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα, Oncotarget, Vol. 7, No. 23: 33866-33886.
  • Thomas DM et al. Diagnosis and Management of Hereditary Sarcoma. Recent Results Cancer Res. 2016;205:169-89.
  • Topkas, E, Cai, N, Cumming A, Saunders NA, Endo-Munoz L. Auranofin is a potent suppressor of osteosarcoma metastasis. Oncotarget 7:831-844, 2016.
  • WALIA MK, Ho PM, Taylor S, Ng AJ, Gupte A, Chalk AM, Zannettino AC, Martin TJ, Walkley CR. Activation of PTHrP-cAMP-CREB1 signaling following p53 loss is essential for osteosarcoma initiation and maintenance. eLife. 2016 Apr 12;5. pii: e13446. doi:10.7554.
  • Xiaochun Wang, David Goldstein, Philip J. Crowe, Mark Yang, Kerryn Garrett, Nikolajs Zeps and Jia-Lin Yang. Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma. Oncotarget (2016); 7(16):21496-215.
  • Ballinger ML, Mitchell G, Thomas DM. Surveillance recommendations for patients with germ-line TP53 mutations. Current Opinion in Oncology 2015, Vol 27 No 4 p332-337.
  • Broadhead ML, Lokmic Z, Tan ML, Stevenson A, Binns DS, Cullinane C, Hicks RJ, Choong PF, Myers DE. Applying Advanced Imaging Techniques to a Murine Model of Orthotopic Osteosarcoma. Frontiers in surgery 2 : 36(2015).
  • Gupte A et al. Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma. Clin Cancer Res. 2015;21:3216-29.
  • Kate McBride; Nina Hallowell; Martin H.N. Tattersall ; Judy Kirk ; Mandy L. Ballinger; David M. Thomas; Gillian Mitchell & Mary-Anne Young. Timing and Context: Important considerations in the return of genetic results to research participants. Journal of Community Genetics 2015, DOI 10.1007/s12687-015-0231-7.
  • McBride et al. An international survey of awareness of genetic risk in the clinical sarcoma community, 2015 Asia Pacific Journal of Clincal Oncology.
  • Mirabello L et al. A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma. Cancer Discov. 2015;5:920-31.
  • Pishas KI, Adwal A, Neuhaus SJ, Clayer MT, Farshid G, Staudacher AH & Callen DF. XI-006 induces potent p53-independent apoptosis in Ewing sarcoma. Sci Rep. 2015 Jun 22;5:11465.
  • Sampson JN et al. Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. J Natl Cancer Inst. 2015;107.
  • Thomas DM, Ballinger ML. Etiologic, environmental and inherited risk factors in sarcomas. J Surg Oncol. 2015 Apr;111(5):490-5. doi: 10.1002/jso.23809. Epub 2014 Oct 21.
  • Thomas DM, James PA, Ballinger ML. Personal View - Clinical implications of genomics for cancer risk genetics. Lancet Oncology 2015; 16:e303-08.
  • Chawla SP et al. Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. J Clin Oncol. 2014;32:3299-306.
  • Judson I et al. Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma. Clin Cancer Res. 2014;20:3603-12.
  • Lewin J et al. A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma. Br J Cancer. 2014;111:2254-61.
  • McBride, K. A., Ballinger, M. L., Killick, E., Kirk, J., Tattersall, M. H. N., Eeles, R. A. Mitchell, G. (2014). Li-Fraumeni syndrome: cancer risk assessment and clinical management. Nature Reviews Clinical Oncology, 11(5), 260-271. doi:10.1038/nrc.
  • Pishas KI, Neuhaus SJ, Clayer MT, Schreiber AW et al. Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling. Cancer Research. 2014 Feb 1;74(3):921-31.
  • Cain JE, McCaw A, Jayasekara S, Rossello FJ, Marini KD, Irving AT, Kansara M, Thomas DM, Ashley DM, Watkins DN.  Sustained Treatment With Low Dose Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells. Sarcoma, 2013.
  • Collins M et al. Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J Clin Oncol. 2013;31:2303-12.
  • Mitchell G et al. High frequency of germline TP53 mutations in a prospective adult-onset sarcoma cohort. PLoS One. 2013;8.
  • Pishas KI, Neuhaus SJ, Clayer MT, Adwal A, Brown MP, Evdokiou A, et al. Pre-activation of the p53 pathway through Nutlin-3a sensitises sarcomas to Drozitumab therapy. Oncology Reports. 2013 Jul;30(1):471-7.
  • Savage et al. Genome-wide association study identifies novel loci associated with osteosarcoma, 2013 Nature Genetics Vol 45 No 7, p799.
  • Young, M-A, Herlihy A, Thomas D, Ballinger M, Tucker K, Neuhaus S, Halliday J. 'The attitudes of people with sarcoma and their family towards genomics and incidental information arising from genetic research' Clinical Sarcoma Res. 2013 Jul 30;3(1):11.
  • Downing et al. An increased incidence of Hodgkin’s lymphoma in patients with adult-onset sarcoma, Clinical Sarcoma Research 2012, 2:1
  • Broadhead, Matthew L and Clark, Jonathan C. M and Dass, Crispin R and Choong, Peter F. M and Myers, Damian E (2011) Therapeutic targeting of osteoclast function and pathways. Expert Opinion on Therapeutic Targets, 15 (2). pp. 169-181. ISSN 1472-8222.
  • Choong, Peter F. M and Broadhead, Matthew L and Clark, Jonathan C. M and Myers, Damian E and Dass, Crispin R (2011) The molecular pathogenesis of osteosarcoma: A review. Sarcoma, 2011. pp. 1-12. ISSN 1357-714X.
  • Neilsen PM, Pishas KI, Callen DF and Thomas DM. Targeting the p53 pathway in Ewing Sarcoma. Sarcoma. 2011:746939.
  • Pishas KI, Al-Ejeh F, Zinonos I, Brown MP, Evdokiou A, Callen DF and Neilsen PM. Nutlin-3a is a potential therapeutic for Ewing Sarcoma. Clinical Cancer Research. 2011; 17(3):494-504.

Information accurate as of 10 May 2019